U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H27ClN2O8
Molecular Weight 518.943
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLUCAMETACIN

SMILES

COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO

InChI

InChIKey=XLVXAUNDHWERBM-IVGWJTKZSA-N
InChI=1S/C25H27ClN2O8/c1-13-17(10-22(32)27-19(11-29)23(33)24(34)21(31)12-30)18-9-16(36-2)7-8-20(18)28(13)25(35)14-3-5-15(26)6-4-14/h3-9,11,19,21,23-24,30-31,33-34H,10,12H2,1-2H3,(H,27,32)/t19-,21+,23+,24+/m0/s1

HIDE SMILES / InChI
Molecular Formula C25H27ClN2O8
Molecular Weight 518.943
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Glucametacin is a non-steroidal anti-inflammatory, analgesic, antipyretic agent. Glucametacin was compared with ketoprofen in a double-blind, crossover trial. The drugs were given in total daily doses of 420 mg glucametacin and 300 mg ketoprofen for 20 days to 30 patients with chronic arthropathies of an inflammatory or degenerative nature. Both drugs were well tolerated and resulted in significant improvements in a number of criteria of disease assessment. Although there were no significant differences between results seen with the two drugs, there appeared to be trends in favour of glucametacin in respect to both efficacy and tolerance.

Originator

Approval Year

2012
595
PubMed

PubMed

TitleDatePubMed
Further studies on glucametacin in rheumatoid arthritis and in other chronic types of rheumatism.
1981
Double-blind comparison of glucametacin and ketoprofen in chronic arthropathies.
1983
Patents

Patents

JP2002541233A
400
JP2003515526A
462
JP2003528044A
30

Sample Use Guides

In Vivo Use Guide
Twenty-three patients with rheumatoid arthritis and 9 patients with other forms of rheumatic diseases were treated for 20 days with 420 mg glucametacin per day, given as three 140 mg capsules.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:29:34 GMT 2023
Edited
by admin
on Fri Dec 15 15:29:34 GMT 2023
Record UNII
N1EXE5EHAN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GLUCAMETACIN
INN   MART.   MI   WHO-DD  
INN  
Official Name English
2-(2-(1-(P-CHLOROBENZOYL)-5-METHOXY-2-METHYLINDOL-3-YL)ACETAMIDO)-2-DEOXY-D-GLUCOSE
Common Name English
GLUCAMETACIN [MI]
Common Name English
GLUCAMETAN
Brand Name English
GLUCAMETACINE
Common Name English
glucametacin [INN]
Common Name English
Glucametacin [WHO-DD]
Common Name English
2-(1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-1H-INDOL-3-YL)-N-((3R,4R,5S,6R)-2,4,5-TRIHYDROXY-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3-YL)ACETAMIDE
Systematic Name English
GLUCAMETACIN [MART.]
Common Name English
2-(1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-1H-INDOL-3-YL)-N-((2R,3R,4S,5R)-3,4,5,6-TETRAHYDROXY-1-OXOHEXAN-2-YL)ACETAMIDE
Systematic Name English
GLUCAMETHACIN
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C257
Created by admin on Fri Dec 15 15:29:34 GMT 2023 , Edited by admin on Fri Dec 15 15:29:34 GMT 2023
Code System Code Type Description
CAS
52443-21-7
Created by admin on Fri Dec 15 15:29:34 GMT 2023 , Edited by admin on Fri Dec 15 15:29:34 GMT 2023
PRIMARY
EVMPD
SUB07936MIG
Created by admin on Fri Dec 15 15:29:34 GMT 2023 , Edited by admin on Fri Dec 15 15:29:34 GMT 2023
PRIMARY
RXCUI
25834
Created by admin on Fri Dec 15 15:29:34 GMT 2023 , Edited by admin on Fri Dec 15 15:29:34 GMT 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
257-923-9
Created by admin on Fri Dec 15 15:29:34 GMT 2023 , Edited by admin on Fri Dec 15 15:29:34 GMT 2023
PRIMARY
MESH
C010581
Created by admin on Fri Dec 15 15:29:34 GMT 2023 , Edited by admin on Fri Dec 15 15:29:34 GMT 2023
PRIMARY
DRUG CENTRAL
1306
Created by admin on Fri Dec 15 15:29:34 GMT 2023 , Edited by admin on Fri Dec 15 15:29:34 GMT 2023
PRIMARY
ChEMBL
CHEMBL2107410
Created by admin on Fri Dec 15 15:29:34 GMT 2023 , Edited by admin on Fri Dec 15 15:29:34 GMT 2023
PRIMARY
DAILYMED
N1EXE5EHAN
Created by admin on Fri Dec 15 15:29:34 GMT 2023 , Edited by admin on Fri Dec 15 15:29:34 GMT 2023
PRIMARY
FDA UNII
N1EXE5EHAN
Created by admin on Fri Dec 15 15:29:34 GMT 2023 , Edited by admin on Fri Dec 15 15:29:34 GMT 2023
PRIMARY
INN
3711
Created by admin on Fri Dec 15 15:29:34 GMT 2023 , Edited by admin on Fri Dec 15 15:29:34 GMT 2023
PRIMARY
SMS_ID
100000084226
Created by admin on Fri Dec 15 15:29:34 GMT 2023 , Edited by admin on Fri Dec 15 15:29:34 GMT 2023
PRIMARY
MERCK INDEX
m5753
Created by admin on Fri Dec 15 15:29:34 GMT 2023 , Edited by admin on Fri Dec 15 15:29:34 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C80554
Created by admin on Fri Dec 15 15:29:34 GMT 2023 , Edited by admin on Fri Dec 15 15:29:34 GMT 2023
PRIMARY
EPA CompTox
DTXSID80200445
Created by admin on Fri Dec 15 15:29:34 GMT 2023 , Edited by admin on Fri Dec 15 15:29:34 GMT 2023
PRIMARY
PUBCHEM
3033980
Created by admin on Fri Dec 15 15:29:34 GMT 2023 , Edited by admin on Fri Dec 15 15:29:34 GMT 2023
PRIMARY
Related Record Type Details
Structure of GLUCAMETACIN MONOHYDRATE
SOLVATE->ANHYDROUS
Related Record Type Details
Structure of GLUCAMETACIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966